Overview

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Status:
Recruiting
Trial end date:
2033-07-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Joseph Kim
Collaborators:
Exelixis
Merck Sharp & Dohme Corp.
Treatments:
Pembrolizumab